Last reviewed · How we verify

NCT06048380

The Effects of Ripasudil in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Femtosecond Laser Assisted Cataract Surgery

Recruiting now Phase 3 Last updated 27 January 2025
What this trial tests

Phase 3 trial testing Ripasudil in Fuchs' Endothelial Dystrophy in 120 participants. Currently enrolling.

Timeline
1 March 2025
Primary endpoint
1 July 2025
1 July 2025

Quick facts

Lead sponsorSingapore Eye Research Institute
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment120
Start date1 March 2025
Primary completion1 July 2025
Estimated completion1 July 2025
Sites1 location across Singapore

Drugs / interventions tested

Conditions studied

Sponsor

Singapore Eye Research Institute

Who can join

Adults 50 to 100, any sex, with Fuchs' Endothelial Dystrophy or Cataract. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this research is to investigate the effects of ripasudil administered as an ophthalmic solution in patients with FED after femtosecond laser assisted cataract surgery. The secondary aim is to identity the characteristics of patients who will benefit the most with the use of ripasudil based on the test results obtained from this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ripasudil

Trials testing the same drug.

Other recruiting trials for Fuchs' Endothelial Dystrophy

Currently open trials in the same condition.

Other Singapore Eye Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06048380.